Company announcement
Gary A. Gelbfish, MD, FACS, Advances Vascular Care Through Surgical Excellence And Innovation
Board-Certified Vascular Surgeon Combines Decades of Clinical Expertise, Advanced Techniques, and a Commitment to Improving Patient Outcomes
New York City, New York Jul 29, 2026 (Issuewire.com) - Gary A. Gelbfish, MD, FACS, is a distinguished board-certified vascular surgeon with more than four decades of specialized clinical experience dedicated to advancing the diagnosis, treatment, and management of vascular conditions. Through a combination of innovative surgical techniques, personalized care, and a commitment to excellence, Dr. Gelbfish has built a respected career focused on improving vascular health and patient outcomes.
Dr. Gelbfish is affiliated with Mount Sinai Health System, including Mount Sinai Brooklyn and Mount Sinai Beth Israel, and serves as an Assistant Clinical Professor of Surgery at Icahn School of Medicine at Mount Sinai. In these roles, he contributes to both patient care and the education of future healthcare professionals.
Dr. Gelbfish earned his Medical Degree from Columbia University Vagelos College of Physicians and Surgeons before completing his general surgery residency at Maimonides Medical Center. He continued his advanced training through a vascular surgery fellowship at Maimonides Medical Center, developing expertise in both open surgical procedures and minimally invasive endovascular interventions. He is board-certified in vascular surgery and is a Fellow of the American College of Surgeons (FACS).
Throughout his career, Dr. Gelbfish has become known for his meticulous attention to detail, technical precision, and patient-first philosophy. He treats a wide range of arterial and venous disorders, including aneurysms, carotid artery disease, peripheral artery disease, varicose veins, and deep vein thrombosis. By combining advanced procedures with individualized treatment plans, he works to provide comprehensive solutions tailored to each patient's unique needs.
Beyond his clinical practice, Dr. Gelbfish is recognized as an innovator in vascular technology. He holds multiple patents for medical devices designed to improve clot removal, reflecting his ongoing dedication to advancing treatment options and improving the effectiveness of vascular interventions.
Dr. Gelbfish also places strong emphasis on education and collaboration. Through patient and physician seminars, he promotes awareness of vascular disease prevention, early detection, and available treatment options. His outreach efforts support stronger partnerships among specialists, including cardiologists, radiologists, and primary care providers, helping create coordinated approaches to vascular care.
Dr. Gelbfish attributes his success to the belief that "if it's worth doing, it's worth doing well." He credits his father with teaching him the importance of practical perfectionism, high standards, and dedication to continuous improvement. Throughout his career, he has carried forward those principles by remaining committed to lifelong learning, demanding excellence from himself, and providing patients with thoughtful, compassionate, and highly skilled care.
With decades of experience, a passion for innovation, and an unwavering commitment to his patients, Dr. Gary A. Gelbfish continues to make meaningful contributions to the field of vascular surgery while helping shape the future of specialized cardiovascular care.
Learn More about Dr. Gary A. Gelbfish:
Through his findatopdoc profile, https://www.findatopdoc.com/doctor/2917936-Gary-Gelbfish-Vascular-Surgeon or through his profile on Mount Sinai, https://profiles.mountsinai.org/gary-a-gelbfish
About FindaTopDoc.com
FindaTopDoc is a digital health information company that helps connect patients with local physicians and specialists who accept their insurance. Our goal is to help guide you on your journey towards optimal health by providing you with the know-how to make informed decisions for you and your family.
Source :Dr. Gary A. Gelbfish
This article was originally published by IssueWire. Read the original article here.
This announcement was published as provided by the company. The World Insiders editorial team did not write or edit it.